Angelo Corti Selected Research

NGR peptide

5/2016	NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors.
9/2012	Targeted drug delivery and penetration into solid tumors.
3/2012	Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.
8/2011	Tumor vasculature targeting through NGR peptide-based drug delivery systems.
10/2008	The neovasculature homing motif NGR: more than meets the eye.
4/2006	Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.
11/2003	Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
12/2002	Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angelo Corti Research Topics

Disease

74	Neoplasms (Cancer) 01/2022 - 02/2002
11	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2019 - 02/2002
10	Neuroblastoma 01/2019 - 11/2003
8	Inflammation (Inflammations) 11/2019 - 01/2009
7	Adenocarcinoma 01/2020 - 02/2002
7	Melanoma (Melanoma, Malignant) 02/2016 - 05/2003
6	Lymphoma (Lymphomas) 11/2020 - 02/2002
5	Heart Failure 11/2019 - 03/2004
4	Hypertension (High Blood Pressure) 11/2019 - 03/2010
4	Disease Progression 01/2019 - 01/2015
3	Hypoxia (Hypoxemia) 10/2021 - 11/2011
3	Fibrosarcoma 05/2021 - 05/2016
3	Rheumatoid Arthritis 11/2019 - 06/2006
3	Prostatic Neoplasms (Prostate Cancer) 11/2019 - 07/2008
3	Insulin Resistance 11/2019 - 01/2017
3	Shock 09/2019 - 08/2012
3	Critical Illness (Critically Ill) 09/2019 - 08/2012
3	Erdheim-Chester Disease 07/2016 - 10/2012
2	Systolic Heart Failure 02/2022 - 01/2013
2	COVID-19 01/2022 - 10/2021
2	Atherosclerosis 11/2019 - 06/2017
2	Obesity 11/2019 - 01/2018
2	Neoplasm Metastasis (Metastasis) 02/2016 - 07/2008
2	Multiple Myeloma 01/2016 - 01/2015
2	Chills 11/2014 - 01/2010
2	Vascular Tissue Neoplasms 12/2013 - 12/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2010 - 08/2007
2	Necrosis 01/2010 - 07/2006
1	Respiratory Insufficiency (Respiratory Failure) 01/2022
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022
1	Brain Neoplasms (Brain Tumor) 05/2021
1	Hypertrophy 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2020

Drug/Important Bio-Agent (IBA)

43	Peptides (Polypeptides)IBA 01/2022 - 02/2002
36	Chromogranin AIBA 02/2022 - 02/2002
28	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2021 - 02/2002
25	Pharmaceutical PreparationsIBA 01/2022 - 02/2002
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2002
18	LigandsIBA 01/2022 - 01/2004
18	CytokinesIBA 10/2021 - 08/2002
15	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2021 - 08/2002
14	vasostatin IIBA 02/2022 - 03/2006
11	Biomarkers (Surrogate Marker)IBA 02/2022 - 02/2002
11	Liposomes (Liposome)IBA 01/2019 - 11/2003
9	IntegrinsIBA 01/2022 - 01/2004
9	CD13 Antigens (Alanine Aminopeptidase)IBA 12/2013 - 11/2003
8	AntibodiesIBA 01/2019 - 02/2002
8	NGR peptideIBA 05/2016 - 12/2002
5	GoldIBA 05/2021 - 03/2013
5	human CNGRC fusion protein tumor necrosis factor-alphaIBA 11/2020 - 01/2010
5	chromogranin A (344-364)IBA 11/2019 - 10/2012
5	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 01/2012
5	AntigensIBA 01/2017 - 01/2004
4	Biological ProductsIBA 01/2019 - 05/2003
4	Isoaspartic Acid (Isoaspartate)IBA 09/2017 - 09/2008
4	Glycine (Aminoacetic Acid)FDA LinkGeneric 09/2017 - 09/2008
4	Protein Isoforms (Isoforms)IBA 01/2010 - 02/2002
3	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 11/2015
3	Monoclonal AntibodiesIBA 01/2018 - 01/2011
3	Cyclic PeptidesIBA 01/2018 - 12/2002
3	liposomal doxorubicin (Doxil)FDA Link 09/2017 - 11/2003
3	Melphalan (Alkeran)FDA LinkGeneric 09/2011 - 01/2004
3	Arginine (L-Arginine)FDA Link 03/2010 - 09/2008
3	EnzymesIBA 12/2008 - 08/2007
3	Complementary DNA (cDNA)IBA 10/2004 - 02/2002
2	IronIBA 10/2021 - 11/2015
2	Interleukin-12 (IL 12)IBA 05/2021 - 11/2019
2	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021 - 01/2013
2	AlbuminsIBA 09/2019 - 03/2013
2	Neuropilin-1IBA 01/2019 - 11/2018
2	Coloring Agents (Dyes)IBA 11/2018 - 01/2011
2	LipidsIBA 01/2018 - 01/2009
2	Hormones (Hormone)IBA 07/2016 - 12/2010
2	Fibrinolysin FDA Link 01/2016 - 11/2002
2	Infliximab (Remicade)FDA Link 01/2014 - 10/2012
2	ChromograninsIBA 10/2012 - 02/2011
2	vasectrin I (VS I)IBA 09/2012 - 08/2012
2	ChemokinesIBA 09/2012 - 03/2012
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 08/2007 - 08/2002
2	Biotin (Vitamin H)FDA Link 02/2004 - 05/2003
2	AvidinIBA 02/2004 - 05/2003
1	C-Reactive ProteinIBA 01/2022
1	SaporinsIBA 01/2022
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2022
1	lactate dehydrogenase C4IBA 10/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2021
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2021
1	AlarminsIBA 10/2021
1	AdipokinesIBA 10/2021
1	CreatinineIBA 10/2021
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2021
1	Vincristine (Oncovin)FDA LinkGeneric 11/2020
1	Rituximab (Mabthera)FDA Link 11/2020
1	Prednisone (Sone)FDA LinkGeneric 11/2020

Therapy/Procedure

26	Therapeutics 01/2022 - 02/2002
13	Drug Therapy (Chemotherapy) 10/2020 - 08/2002
3	Immunotherapy 01/2018 - 03/2012
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2018 - 01/2017
1	Art Therapy 01/2022
1	Nanospheres 05/2021